グローバルペット用抗腫瘍薬市場規模、主要企業シェア、ランキング分析レポート【2026年版】
Pet Antineoplastic Drug - Global Top Players Market Share and Ranking 2026
- レポートID：99256
- 発表時期：2026-03-19
- レポート形式：PDF
- 産業カテゴリー：薬品及びサプリメント
- レポート言語：英語、日本語
- ページ数：83
- 発行会社（調査会社）：YHResearch
言語とエディションの価格
- 英語版
- 日本語版
- 英語と日本語版
個人版詳細
マルチユーザー版詳細
企業版詳細
- 英語版
- 日本語版
- 英語と日本語版
価格表記: USDを日本円(税抜)に換算，本日の銀行送金レート: 1USD=159.00円。
※米ドル表示価格+10％消費税。
※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。
レポートの概要
本報告書は、世界のペット用抗腫瘍薬市場について包括的な分析を行い、市場全体の動向を明らかにすることを目的としています。総販売数量、売上高、価格動向に加え、主要企業の市場シェアおよび順位を整理し、市場構造を多角的に把握します。さらに、地域・国別、製品タイプ別、用途分野別などの観点からペット用抗腫瘍薬市場を分析し、需要構造と成長特性を明確化します。
ペット用抗腫瘍薬市場の規模、推定値および予測は、2025年を基準年とし、2021年から2032年までの期間における販売数量および売上高に基づいて提示しています。定量分析と定性分析を組み合わせることで、ビジネスおよび成長戦略を検討し、市場競争環境を評価し、企業の市場ポジションを把握した上で、ペット用抗腫瘍薬に関する的確な意思決定を行うための実践的なインサイトを提供します。
主要ペット用抗腫瘍薬市場の統計
2025年世界市場規模：428百万米ドル
2026年世界市場規模：487百万米ドル
2032年予測市場規模：813百万米ドル
2026–2032年予測期間CAGR：8.9%
本レポートはペット用抗腫瘍薬市場の中長期的な成長動向を定量分析および定性分析の両面から体系的に整理しています。
【市場セグメンテーション】
主要企業・競争環境
ペット用抗腫瘍薬市場の主要企業には以下が含まれます：
Zoetis
Merck Animal Health
Virbac
Elanco
製品別
Oral Drugs
Injectable Drugs
アプリケーション別
Mast Cell Tumor
Melanoma
Others
レポート対象地域
北米：アメリカ、カナダ、その他
アジア太平洋：中国、日本、韓国、東南アジア、インド、オーストラリア、その他
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、オランダ、北欧諸国、その他
ラテンアメリカ：メキシコ、ブラジル、その他
中東・アフリカ：トルコ、サウジアラビア、UAE、その他
レポート構成（章別概要）
第1章｜市場概要と成長展望
ペット用抗腫瘍薬市場の全体像を整理し、市場規模、売上予測、価格推移を体系的に解説します。同時に成長要因、市場機会、業界課題、リスク要因を分析し、中長期的な市場展望を提示します
第2章｜主要企業の競争分析
ペット用抗腫瘍薬市場における主要プレイヤー（トップ5社・トップ10社）を対象に、売上高、製造拠点、製品構成、価格戦略、販売量、市場シェアを多面的に分析し、競争構造を明確化します
第3章｜製品カテゴリ別市場動向
製品タイプ別にペット用抗腫瘍薬市場を分類し、売上高、市場シェア、販売量、価格動向を分析します。成長性の高い製品分野と市場構造の変化を明らかにします
第4章｜用途別市場動向
用途別にペット用抗腫瘍薬市場規模、売上高、市場シェア、販売量、価格推移を整理し、業界別の需要動向と成長ポテンシャルを分析します
第5章｜地域別市場分析
地域別の市場成長率、販売量、売上高を詳細に分析し、ペット用抗腫瘍薬市場の地理的需要構造を可視化します。各地域の市場規模推移と将来の成長余地を評価します
第6章｜国別市場動向
主要国・地域ごとに、ペット用抗腫瘍薬市場の販売量、売上高、成長要因、政策・規制環境、競争特性を整理し、国別市場の特徴を明確にします
第7章｜主要企業プロファイル
ペット用抗腫瘍薬市場を牽引する主要企業について、売上高、販売量、価格動向、粗利益率、製品ポートフォリオ、最新の戦略動向を詳細に解説します
第8章｜バリューチェーンと市場構造分析
業界全体のサプライチェーンを上流から下流まで整理し、コスト構造や流通モデルの動向を分析します
第9章｜調査結果
調査結果を総括し、市場全体のトレンド、今後の成長機会、潜在的リスク、戦略的な洞察を提示します
第10章｜付録（調査手法・データソース）
調査設計、分析手法、使用データソースの詳細を明示し、レポートの信頼性と透明性を担保します
本レポートの要点と洞察
ペット用抗腫瘍薬市場の全体像と成長見通し
ペット用抗腫瘍薬市場の規模変化の傾向、成長予測及び需要動向を体系的に整理いたします。2021年から2025年までの実績データに基づき、2032年までの中長期予測を提示し、市場の拡大速度と成長潜在力を明らかにします。同時に、最近の関税調整措置など各国の政策動向を踏まえ、多角的にグローバル経済環境がペット用抗腫瘍薬市場に与える影響を分析いたします
市場環境の構成要素とマクロトレンド
ペット用抗腫瘍薬産業を取り巻く市場環境について、需要構造の変化、政策対応、技術革新の進展といった主要要因を整理します。特に、国際貿易政策や関税政策の変化が企業戦略や価格形成に及ぼす影響、サプライチェーン再編の動きと事業運営への波及効果を明確化し、市場環境の全体像を包括的に提示します
競争構造と主要企業の動向分析
ペット用抗腫瘍薬市場における主要企業の売上規模、市場シェア、競争ポジションを整理し、競争構造の特徴を分析します。各社の競争戦略、事業拡大の方向性、新製品・新技術の投入動向を通じて、技術革新が市場競争に与える影響と競争環境の変化を解読します
競争環境と事業動向の把握
製品タイプ別、用途別、地域・国別の観点からペット用抗腫瘍薬市場のセグメント構造を整理します。各地域の需要構成と成長特性を比較分析し、各細分領域が市場全体の成長に与える貢献度と相互関連性を明確にします
成長要因・課題・リスクの分析
ペット用抗腫瘍薬市場の成長を支える主要ドライバーを整理するとともに、業界特有の課題や潜在的リスクを分析します。原材料調達、供給システム、事業運営における不確実性を踏まえ、サプライチェーン及び事業レジリエンス強化の方向性についても考察します
将来トレンドと市場展望
ペット用抗腫瘍薬市場の中長期的な成長トレンドと将来の発展シナリオを提示します。持続的成長を実現するための重要な成功要因を整理し、今後の市場参入企業や既存プレイヤーの戦略的意思決定に参考となる視点を提供いたします
Description
According to YH Research, the global market for Pet Antineoplastic Drug should grow from US$ 428 million in 2025 to US$ 813 million by 2032, with a CAGR of 8.9% for the period of 2026-2032.
Pet antineoplastic drugs are specialized medications used in veterinary medicine to treat cancer in pets (dogs, cats, horses), often called chemotherapy or cytotoxic agents. They target and destroy cancer cells or inhibit their growth, often utilized alongside surgery or radiation to manage malignant tumors like lymphoma, mast cell tumors, and sarcomas.
The global pet antineoplastic drug market is undergoing a strategic transition from conventional chemotherapy to precision medicine. The market is primarily propelled by the "pet humanization" trend, which has significantly increased healthcare spending on companion animals. Corporate filings indicate that the companion animal segment has become a vital growth engine for biopharmaceutical giants. In terms of innovation, R&D focus has shifted from broad-spectrum cytotoxic agents to targeted therapies, including tyrosine kinase inhibitors and monoclonal antibodies. The FDA’s utilization of "Conditional Approval" pathways for canine lymphoma and mast cell tumor treatments underscores a regulatory commitment to addressing unmet medical needs in veterinary oncology. Furthermore, the rising prevalence of oral formulations is facilitating a shift from clinical administration to at-home care, prioritizing the quality of life for pets. Advancements in early diagnostics, particularly the integration of liquid biopsy screening, present substantial opportunities by accelerating the demand for early-stage intervention. However, several factors hinder market expansion. High R&D expenditures relative to the specialized patient population result in elevated treatment costs. Additionally, the clinical penetration of novel precision drugs is often restricted by a learning curve among general practitioners. Most critically, the lack of comprehensive pet insurance frameworks, compared to human healthcare, remains a fundamental barrier to the affordability and widespread adoption of advanced oncological therapies.
This report studies and analyses global Pet Antineoplastic Drug status and future trends, to help determine the Pet Antineoplastic Drug market size of the total market opportunity by Type, by Application, by company, and by region & country. This report is a detailed and comprehensive analysis of the world market for Pet Antineoplastic Drug, and provides market size (US$ million) and Year-over-Year growth, considering 2025 as the base year.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
To assess the competitive environment within the market including supplier revenue, market share, and company profiles.
Highlights
(1) Global Pet Antineoplastic Drug market size, history data 2021-2025, and forecast data 2026 -2032, (US$ million)
(2) Global Pet Antineoplastic Drug by company, revenue, market share and industry ranking 2021-2026, (US$ million)
(3) Japan Pet Antineoplastic Drug by company, revenue, market share and industry ranking 2021-2026, (US$ million)
(4) Global Pet Antineoplastic Drug key consuming regions, consumption value and demand structure
(5) Pet Antineoplastic Drug industry chains, upstream, midstream and downstream
Market segment by players, this report covers
Zoetis
Merck Animal Health
Virbac
Elanco
Market segment by Type, covers
Oral Drugs
Injectable Drugs
Market segment by Treatment Method, covers
Chemotherapy
Immunotherapy
Others
Market segment by Pet Type, covers
Dogs
Cats
Others
Market segment by Application, can be divided into
Mast Cell Tumor
Melanoma
Others
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Report Includes:
Chapter 1: to describe Pet Antineoplastic Drug product scope, global consumption value, Japan consumption value, development opportunities, challenges, trends, and policies
Chapter 2: Global Pet Antineoplastic Drug market share and ranking of major manufacturers, revenue, 2021-2026
Chapter 3: Japan Pet Antineoplastic Drug market share and ranking of major manufacturers, revenue, 2021-2026
Chapter 4: Pet Antineoplastic Drug industry chain, upstream, medium-stream, and downstream
Chapter 5: Segment by Type, consumption value, percent & CAGR, 2021-2032
Chapter 6: Segment by Application, consumption value, percent & CAGR, 2021-2032
Chapter 7: Segment in regional level, consumption value, percent & CAGR, 2021-2032
Chapter 8: Segment in country level, consumption value, percent & CAGR, 2021-2032
Chapter 9: Company profile, introducing the basic situation of the main companies in the market in detail, including product specifications, application, recent development, revenue, gross margin
Chapter 10: Conclusions
Table of Contents
1 Market Overview
1.1 Pet Antineoplastic Drug Definition
1.2 Global Pet Antineoplastic Drug Market Size and Forecast
1.3 Japan Pet Antineoplastic Drug Market Size and Forecast
1.4 Share of Japan Pet Antineoplastic Drug Market with Respect to the Global Market
1.5 Pet Antineoplastic Drug Market Size: Japan VS Global Growth Rate, 2021-2032
1.6 Pet Antineoplastic Drug Market Dynamics
1.6.1 Pet Antineoplastic Drug Market Drivers
1.6.2 Pet Antineoplastic Drug Market Restraints
1.6.3 Pet Antineoplastic Drug Industry Trends
1.6.4 Pet Antineoplastic Drug Industry Policy
2 Global Leading Players and Market Share
2.1 By Revenue of Pet Antineoplastic Drug, Global Market Share by Company, 2021-2026
2.2 Global Pet Antineoplastic Drug Participants, Market Position (Tier 1, Tier 2, and Tier 3)
2.3 Global Pet Antineoplastic Drug Concentration Ratio
2.4 Global Pet Antineoplastic Drug Mergers & Acquisitions, Expansion Plans
2.5 Global Pet Antineoplastic Drug Major Companies Product Type
2.6 Head Office and Area Served of Key Players
3 Japan Leading Players, Market Share and Ranking
3.1 By Revenue of Pet Antineoplastic Drug, Japan Market Share by Company, 2021-2026
3.2 Japan Pet Antineoplastic Drug Pet Antineoplastic Drug Participants, Market Position (Tier 1, Tier 2, and Tier 3)
4 Industry Chain Analysis
4.1 Pet Antineoplastic Drug Industry Chain
4.2 Pet Antineoplastic Drug Upstream Analysis
4.2.1 Pet Antineoplastic Drug Core Raw Materials
4.2.2 Main Manufacturers of Pet Antineoplastic Drug Core Raw Materials
4.3 Midstream Analysis
4.4 Downstream Analysis
4.5 Pet Antineoplastic Drug Production Mode
4.6 Pet Antineoplastic Drug Procurement Model
4.7 Pet Antineoplastic Drug Industry Sales Model and Sales Channels
4.7.1 Pet Antineoplastic Drug Sales Model
4.7.2 Pet Antineoplastic Drug Typical Distributors
5 Sights Pet Antineoplastic Drug Market Classification
5.1 Pet Antineoplastic Drug Classification by Type
5.1.1 Oral Drugs
5.1.2 Injectable Drugs
5.1.3 by Type, Global Pet Antineoplastic Drug Consumption Value & CAGR, 2021 VS 2025 VS 2032
5.1.4 by Type, Global Pet Antineoplastic Drug Consumption Value, 2021-2032
5.2 Pet Antineoplastic Drug Classification by Treatment Method
5.2.1 Chemotherapy
5.2.2 Immunotherapy
5.2.3 Others
5.2.4 by Treatment Method, Global Pet Antineoplastic Drug Consumption Value & CAGR, 2021 VS 2025 VS 2032
5.2.5 by Treatment Method, Global Pet Antineoplastic Drug Consumption Value, 2021-2032
5.3 Pet Antineoplastic Drug Classification by Pet Type
5.3.1 Dogs
5.3.2 Cats
5.3.3 Others
5.3.4 by Pet Type, Global Pet Antineoplastic Drug Consumption Value & CAGR, 2021 VS 2025 VS 2032
5.3.5 by Pet Type, Global Pet Antineoplastic Drug Consumption Value, 2021-2032
6 Sights by Application
6.1 Pet Antineoplastic Drug Segment by Application
6.1.1 Mast Cell Tumor
6.1.2 Melanoma
6.1.3 Others
6.2 by Application, Global Pet Antineoplastic Drug Consumption Value & CAGR, 2021 VS 2025 VS 2032
6.3 by Application, Global Pet Antineoplastic Drug Consumption Value, 2021-2032
7 Sales Sights by Region
7.1 By Region, Global Pet Antineoplastic Drug Consumption Value, 2021 VS 2025 VS 2032
7.2 By Region, Global Pet Antineoplastic Drug Consumption Value, 2021-2032
7.3 North America
7.3.1 North America Pet Antineoplastic Drug Market Size & Forecasts, 2021-2032
7.3.2 By Country, North America Pet Antineoplastic Drug Market Size Market Share
7.4 Europe
7.4.1 Europe Pet Antineoplastic Drug Market Size & Forecasts, 2021-2032
7.4.2 By Country, Europe Pet Antineoplastic Drug Market Size Market Share
7.5 Asia Pacific
7.5.1 Asia Pacific Pet Antineoplastic Drug Market Size & Forecasts, 2021-2032
7.5.2 By Country/Region, Asia Pacific Pet Antineoplastic Drug Market Size Market Share
7.6 South America
7.6.1 South AmericaPet Antineoplastic Drug Market Size & Forecasts, 2021-2032
7.6.2 By Country, South America Pet Antineoplastic Drug Market Size Market Share
7.7 Middle East & Africa
8 Sales Sights by Country Level
8.1 By Country, Global Pet Antineoplastic Drug Market Size & CAGR, 2021 VS 2025 VS 2032
8.2 By Country, Global Pet Antineoplastic Drug Consumption Value, 2021-2032
8.3 United States
8.3.1 United States Pet Antineoplastic Drug Market Size, 2021-2032
8.3.2 by Type, United States Pet Antineoplastic Drug Consumption Value Market Share, 2025 VS 2032
8.3.3 by Application, United States Pet Antineoplastic Drug Consumption Value Market Share, 2025 VS 2032
8.4 Europe
8.4.1 Europe Pet Antineoplastic Drug Market Size, 2021-2032
8.4.2 by Type, Europe Pet Antineoplastic Drug Consumption Value Market Share, 2025 VS 2032
8.4.3 by Application, Europe Pet Antineoplastic Drug Consumption Value Market Share, 2025 VS 2032
8.5 China
8.5.1 China Pet Antineoplastic Drug Market Size, 2021-2032
8.5.2 by Type, China Pet Antineoplastic Drug Consumption Value Market Share, 2025 VS 2032
8.5.3 by Application, China Pet Antineoplastic Drug Consumption Value Market Share, 2025 VS 2032
8.6 Japan
8.6.1 Japan Pet Antineoplastic Drug Market Size, 2021-2032
8.6.2 by Type, Japan Pet Antineoplastic Drug Consumption Value Market Share, 2025 VS 2032
8.6.3 by Application, Japan Pet Antineoplastic Drug Consumption Value Market Share, 2025 VS 2032
8.7 South Korea
8.7.1 South Korea Pet Antineoplastic Drug Market Size, 2021-2032
8.7.2 by Type, South Korea Pet Antineoplastic Drug Consumption Value Market Share, 2025 VS 2032
8.7.3 by Application, South Korea Pet Antineoplastic Drug Consumption Value Market Share, 2025 VS 2032
8.8 Southeast Asia
8.8.1 Southeast Asia Pet Antineoplastic Drug Market Size, 2021-2032
8.8.2 by Type, Southeast Asia Pet Antineoplastic Drug Consumption Value Market Share, 2025 VS 2032
8.8.3 by Application, Southeast Asia Pet Antineoplastic Drug Consumption Value Market Share, 2025 VS 2032
8.9 India
8.9.1 India Pet Antineoplastic Drug Market Size, 2021-2032
8.9.2 by Type, India Pet Antineoplastic Drug Consumption Value Market Share, 2025 VS 2032
8.9.3 by Application, India Pet Antineoplastic Drug Consumption Value Market Share, 2025 VS 2032
8.10 Middle East & Africa
8.10.1 Middle East & Africa Pet Antineoplastic Drug Market Size, 2021-2032
8.10.2 by Type, Middle East & Africa Pet Antineoplastic Drug Consumption Value Market Share, 2025 VS 2032
8.10.3 by Application, Middle East & Africa Pet Antineoplastic Drug Consumption Value Market Share, 2025 VS 2032
9 Company Profile
9.1 Zoetis
9.1.1 Zoetis Company Information, Head Office, Market Area, and Industry Position
9.1.2 Zoetis Company Profile and Main Business
9.1.3 Zoetis Pet Antineoplastic Drug Models, Specifications, and Application
9.1.4 Zoetis Pet Antineoplastic Drug Revenue and Gross Margin, 2021-2026
9.1.5 Zoetis Recent Developments
9.2 Merck Animal Health
9.2.1 Merck Animal Health Company Information, Head Office, Market Area, and Industry Position
9.2.2 Merck Animal Health Company Profile and Main Business
9.2.3 Merck Animal Health Pet Antineoplastic Drug Models, Specifications, and Application
9.2.4 Merck Animal Health Pet Antineoplastic Drug Revenue and Gross Margin, 2021-2026
9.2.5 Merck Animal Health Recent Developments
9.3 Virbac
9.3.1 Virbac Company Information, Head Office, Market Area, and Industry Position
9.3.2 Virbac Company Profile and Main Business
9.3.3 Virbac Pet Antineoplastic Drug Models, Specifications, and Application
9.3.4 Virbac Pet Antineoplastic Drug Revenue and Gross Margin, 2021-2026
9.3.5 Virbac Recent Developments
9.4 Elanco
9.4.1 Elanco Company Information, Head Office, Market Area, and Industry Position
9.4.2 Elanco Company Profile and Main Business
9.4.3 Elanco Pet Antineoplastic Drug Models, Specifications, and Application
9.4.4 Elanco Pet Antineoplastic Drug Revenue and Gross Margin, 2021-2026
9.4.5 Elanco Recent Developments
10 Conclusion
11 Appendix
11.1 Research Methodology
11.2 Data Source
11.2.1 Secondary Sources
11.2.2 Primary Sources
11.3 Market Estimation Model
11.4 Disclaimer
Table of Figures
List of Tables Table 1. Pet Antineoplastic Drug Consumption Value & CAGR: Japan VS Global, 2021-2032, US$ Million Table 2. Pet Antineoplastic Drug Market Restraints Table 3. Pet Antineoplastic Drug Market Trends Table 4. Pet Antineoplastic Drug Industry Policy Table 5. Global Pet Antineoplastic Drug Revenue by Company, 2021-2026, US$ million, Ranked Based on Revenue in 2025 Table 6. Global Pet Antineoplastic Drug Revenue Share by Company, 2021-2026, Ranked by Data of 2025 Table 7. Global Pet Antineoplastic Drug Manufacturers Market Concentration Ratio (CR3 and HHI) Table 8. Global Pet Antineoplastic Drug Mergers & Acquisitions, Expansion Plans Table 9. Global Pet Antineoplastic Drug Major Companies Product Type Table 10. Head Office and Area Served of Key Players Table 11. Japan Pet Antineoplastic Drug Revenue by Company, 2021-2026, US$ million, Ranked Based on Revenue in 2025 Table 12. Japan Pet Antineoplastic Drug Revenue Market Share by Company, 2021-2026 Table 13. Global Key Players of Pet Antineoplastic Drug Upstream (Raw Materials) Table 14. Global Pet Antineoplastic Drug Typical Customers Table 15. Pet Antineoplastic Drug Typical Distributors Table 16. by Type, Global Pet Antineoplastic Drug Consumption Value & CAGR, 2021 VS 2025 VS 2032, US$ Million Table 17. by Treatment Method, Global Pet Antineoplastic Drug Consumption Value & CAGR, 2021 VS 2025 VS 2032, US$ Million Table 18. by Pet Type, Global Pet Antineoplastic Drug Consumption Value & CAGR, 2021 VS 2025 VS 2032, US$ Million Table 19. by Application, Global Pet Antineoplastic Drug Consumption Value & CAGR, 2021 VS 2025 VS 2032, US$ Million Table 20. By Region, Global Pet Antineoplastic Drug Consumption Value, 2021 VS 2025 VS 2032, US$ Million Table 21. By Region, Global Pet Antineoplastic Drug Consumption Value, 2021-2032, US$ Million Table 22. By Country, Global Pet Antineoplastic Drug Consumption Value & CAGR, 2021 VS 2025 VS 2032, US$ Million Table 23. By Country, Global Pet Antineoplastic Drug Consumption Value, 2021-2032, US$ Million Table 24. By Country, Global Pet Antineoplastic Drug Consumption Value Market Share, 2021-2032 Table 25. Zoetis Company Information, Head Office, Market Area, and Industry Position Table 26. Zoetis Company Profile and Main Business Table 27. Zoetis Pet Antineoplastic Drug Models, Specifications, and Application Table 28. Zoetis Pet Antineoplastic Drug Revenue and Gross Margin, US$ Million, 2021-2026 Table 29. Zoetis Recent Developments Table 30. Merck Animal Health Company Information, Head Office, Market Area, and Industry Position Table 31. Merck Animal Health Company Profile and Main Business Table 32. Merck Animal Health Pet Antineoplastic Drug Models, Specifications, and Application Table 33. Merck Animal Health Pet Antineoplastic Drug Revenue and Gross Margin, US$ Million, 2021-2026 Table 34. Merck Animal Health Recent Developments Table 35. Virbac Company Information, Head Office, Market Area, and Industry Position Table 36. Virbac Company Profile and Main Business Table 37. Virbac Pet Antineoplastic Drug Models, Specifications, and Application Table 38. Virbac Pet Antineoplastic Drug Revenue and Gross Margin, US$ Million, 2021-2026 Table 39. Virbac Recent Developments Table 40. Elanco Company Information, Head Office, Market Area, and Industry Position Table 41. Elanco Company Profile and Main Business Table 42. Elanco Pet Antineoplastic Drug Models, Specifications, and Application Table 43. Elanco Pet Antineoplastic Drug Revenue and Gross Margin, US$ Million, 2021-2026 Table 44. Elanco Recent Developments List of Figures Figure 1. Pet Antineoplastic Drug Picture Figure 2. Global Pet Antineoplastic Drug Consumption Value, (US$ million) & (2021-2032) Figure 3. Japan Pet Antineoplastic Drug Consumption Value, (US$ million) & (2021-2032) Figure 4. By Consumption Value, Japan Pet Antineoplastic Drug Market Share of Global, 2021-2032 Figure 5. Global Pet Antineoplastic Drug Market Share by Company, (Tier 1, Tier 2, and Tier 3), 2025 Figure 6. Japan Pet Antineoplastic Drug Key Participants, Market Share, 2025 Figure 7. Pet Antineoplastic Drug Industry Chain Figure 8. Pet Antineoplastic Drug Procurement Model Figure 9. Pet Antineoplastic Drug Sales Model Figure 10. Pet Antineoplastic Drug Sales Channels, Direct Sales, and Distribution Figure 11. Oral Drugs Figure 12. Injectable Drugs Figure 13. by Type, Global Pet Antineoplastic Drug Consumption Value, 2021-2032, US$ Million Figure 14. by Type, Global Pet Antineoplastic Drug Consumption Value Market Share, 2021-2032 Figure 15. Chemotherapy Figure 16. Immunotherapy Figure 17. Others Figure 18. by Treatment Method, Global Pet Antineoplastic Drug Consumption Value, 2021-2032, US$ Million Figure 19. by Treatment Method, Global Pet Antineoplastic Drug Consumption Value Market Share, 2021-2032 Figure 20. Dogs Figure 21. Cats Figure 22. Others Figure 23. by Pet Type, Global Pet Antineoplastic Drug Consumption Value, 2021-2032, US$ Million Figure 24. by Pet Type, Global Pet Antineoplastic Drug Consumption Value Market Share, 2021-2032 Figure 25. Mast Cell Tumor Figure 26. Melanoma Figure 27. Others Figure 28. by Application, Global Pet Antineoplastic Drug Consumption Value, 2021-2032, US$ Million Figure 29. by Application, Global Pet Antineoplastic Drug Revenue Market Share, 2021-2032 Figure 30. By Region, Global Pet Antineoplastic Drug Consumption Value Market Share, 2021-2032 Figure 31. North America Pet Antineoplastic Drug Consumption Value & Forecasts, 2021-2032, US$ Million Figure 32. By Country, North America Pet Antineoplastic Drug Consumption Value Market Share, 2025 Figure 33. Europe Pet Antineoplastic Drug Consumption Value & Forecasts, 2021-2032, US$ Million Figure 34. By Country, Europe Pet Antineoplastic Drug Consumption Value Market Share, 2025 Figure 35. Asia Pacific Pet Antineoplastic Drug Consumption Value & Forecasts, 2021-2032, US$ Million Figure 36. By Country/Region, Asia Pacific Pet Antineoplastic Drug Consumption Value Market Share, 2025 Figure 37. South America Pet Antineoplastic Drug Consumption Value & Forecasts, 2021-2032, US$ Million Figure 38. By Country, South America Pet Antineoplastic Drug Consumption Value Market Share, 2025 Figure 39. Middle East & Africa Pet Antineoplastic Drug Consumption Value & Forecasts, 2021-2032, US$ Million Figure 40. United States Pet Antineoplastic Drug Consumption Value, 2021-2032, US$ Million Figure 41. by Type, United States Pet Antineoplastic Drug Consumption Value Market Share, 2025 VS 2032 Figure 42. by Application, United States Pet Antineoplastic Drug Consumption Value Market Share, 2025 VS 2032 Figure 43. Europe Pet Antineoplastic Drug Consumption Value, 2021-2032, US$ Million Figure 44. by Type, Europe Pet Antineoplastic Drug Consumption Value Market Share, 2025 VS 2032 Figure 45. by Application, Europe Pet Antineoplastic Drug Consumption Value Market Share, 2025 VS 2032 Figure 46. China Pet Antineoplastic Drug Consumption Value, 2021-2032, US$ Million Figure 47. by Type, China Pet Antineoplastic Drug Consumption Value Market Share, 2025 VS 2032 Figure 48. by Application, China Pet Antineoplastic Drug Consumption Value Market Share, 2025 VS 2032 Figure 49. Japan Pet Antineoplastic Drug Consumption Value, 2021-2032, US$ Million Figure 50. by Type, Japan Pet Antineoplastic Drug Consumption Value Market Share, 2025 VS 2032 Figure 51. by Application, Japan Pet Antineoplastic Drug Consumption Value Market Share, 2025 VS 2032 Figure 52. South Korea Pet Antineoplastic Drug Consumption Value, 2021-2032, US$ Million Figure 53. by Type, South Korea Pet Antineoplastic Drug Consumption Value Market Share, 2025 VS 2032 Figure 54. by Application, South Korea Pet Antineoplastic Drug Consumption Value Market Share, 2025 VS 2032 Figure 55. Southeast Asia Pet Antineoplastic Drug Consumption Value, 2021-2032, US$ Million Figure 56. by Type, Southeast Asia Pet Antineoplastic Drug Consumption Value Market Share, 2025 VS 2032 Figure 57. by Application, Southeast Asia Pet Antineoplastic Drug Consumption Value Market Share, 2025 VS 2032 Figure 58. India Pet Antineoplastic Drug Consumption Value, 2021-2032, US$ Million Figure 59. by Type, India Pet Antineoplastic Drug Consumption Value Market Share, 2025 VS 2032 Figure 60. by Application, India Pet Antineoplastic Drug Consumption Value Market Share, 2025 VS 2032 Figure 61. Middle East & Africa Pet Antineoplastic Drug Consumption Value, 2021-2032, US$ Million Figure 62. by Type, Middle East & Africa Pet Antineoplastic Drug Consumption Value Market Share, 2025 VS 2032 Figure 63. by Application, Middle East & Africa Pet Antineoplastic Drug Consumption Value Market Share, 2025 VS 2032 Figure 64. Research Methodology Figure 65. Breakdown of Primary Interviews Figure 66. Bottom-up Approaches Figure 67. Top-down Approaches
お見積>
サンプルお申込み>
今すぐ購入>
PDFダウンロード>
当社から購入のメリット
多言語（英語、日本語）のサンプル提供
プロフェッショナルな日本語翻訳を提供
請求書、クレジットカードでのお支払いが可能です
必要なチャプターやカスタマイズされたレポートの注文が可能
購入後、アナリストに直接連絡することができます
購入方法
必要な言語とバージョンのレポート選択
レポート要件と見積もり依頼
電子メールによる注文
レポートの入手（英語版は2～4営業日、日本語版は8～10営業日）
クレジットカード決済、オフライン振込に対応（後払い可）
クライアント様（例）
050-5840-2692 日本
0081-50-5840-2692 グローバル
info@globalreports.jp